Patents Examined by Stephen Kapushoc
  • Patent number: 8143029
    Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: March 27, 2012
    Assignee: Valipharma
    Inventors: Annamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J. E Krohn
  • Patent number: 8119348
    Abstract: The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: February 21, 2012
    Assignees: The Regents of the University of Michigan, The Trustees of the University of Pennsylvania, Mayo Foundation for Medical Education and Research
    Inventors: Anand Swaroop, Goncalo Abecasis, Wei Chen, Dwight Stambolian, Albert O. Edwards
  • Patent number: 8114596
    Abstract: The described method provides, methods, and kits to produce, identify, catalog and classify a comprehensive collection of nucleic acid targets produced from a nucleic acid sample. The method, referred to as Cataloging and Classification of Sequence Tags, involves generating a set of target nucleic acid fragments; coupling the target nucleic acid fragments to a nucleic acid bridge comprising, for example, two or more primer binding sites and two recognition sites for cleavage at a site offset from the recognition site to the fragment's end; and cleaving the fragments to generate chimeric nucleic acids of known length. The nucleic acid bridge is thus disposed between the two nucleic acid fragments in the chimeric nucleic acid. The resulting duplex nucleic acids comprise a set of sequence tags (i.e., by amplification using universal primers), comprising an addressable portion, a target nucleic portion and a portion of the nucleic acid bridge.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: February 14, 2012
    Inventor: Joseph C. Kaufman
  • Patent number: 8114592
    Abstract: Disclosed is a method for identifying an individual who has an altered risk for developing age related macular degeneration comprising detecting a single nucleotide polymorphism (SNP).
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: February 14, 2012
    Assignee: Cambridge Enterprise Limited
    Inventor: John R. W. Yates
  • Patent number: 8110351
    Abstract: The present invention comprises a method of isolating nucleic acid and protein from the same sample with solid supports, wherein nucleic acid and protein components contained in the sample become bound to distinct solid supports. The invention also allows for kits for isolating nucleic acid and protein from the same sample and for use of the method of isolating nucleic acid and protein for the analysis and/or comparison of mRNA and/or protein expression and/or their correlation to genomic information.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: February 7, 2012
    Assignee: Invitrogen Dynal AS
    Inventor: Marie Bosnes
  • Patent number: 8105846
    Abstract: The invention relates to a method of identifying an individual nucleotide, comprising (a) contacting the nucleotide with a transmembrane protein pore so that the nucleotide interacts with the pore and (b) measuring the current passing through the pore during the interaction and thereby determining the identity of the nucleotide. The invention also relates to a method of sequencing nucleic acid sequences and kits related thereto.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: January 31, 2012
    Assignee: Isis Innovation Limited
    Inventors: Hagan Bayley, Yann Astier, Orit Braha
  • Patent number: 8084202
    Abstract: Embodiments of the invention provide methods for detecting molecular recognition events electronically and optically. Methods according to embodiments of the invention provide a nucleic acid molecule that hybridizes to a first probe nucleic acid molecule attached to an electronic detector wherein the second nucleic acid molecule comprises two regions. The two regions of the second nucleic acid molecule consist of a region that is complementary to the probe nucleic acid and a distal region that is not complementary to the first probe nucleic acid molecule. The hybridization reaction is detected electronically. A third nucleic acid molecule having an attached optically detectable label is hybridized to the distal region of the second nucleic acid molecule and the label is detected optically. Methods according to embodiments of the invention are useful, for example, to validate and quantify electronic detection methods.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: December 27, 2011
    Assignee: Intel Corporation
    Inventor: Hernan A. Castro
  • Patent number: 8071297
    Abstract: The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: December 6, 2011
    Assignee: Sanofi-Aventis
    Inventors: Detlef Kozian, Matthias Herrmann, Thomas Leeuw, Wilfried Renner, Winfried Maerz
  • Patent number: 8071291
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: December 6, 2011
    Assignee: Celera Corporation
    Inventors: Lance Bare, James J. Devlin, Frits R. Rosendaal, Pieter H. Reitsma, Irene D. Bezemer
  • Patent number: 8067171
    Abstract: Single nucleotide polymorphic site at position 11646 of the bovine FGF2 gene is associated with improved fertilization rate and/or improved embryo survival rate, as well as improved milk production. Also disclosed are nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: November 29, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Hasan Khatibm
  • Patent number: 8067168
    Abstract: The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use in detecting and diagnosing cancer.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: November 29, 2011
    Assignee: Orion Genomics LLC
    Inventors: Jared Ordway, Jeffrey A. Jeddeloh, Joseph Bedell
  • Patent number: 8057994
    Abstract: A method of investigating a DNA sample is provided involving taking at least two sub-samples from the sample, amplifying the sub-samples, analyzing the sub-samples to obtain identity information and amount of that identity about one or more alleles indicated as present in the sub-samples in respect of 5 or more loci and establishing identity information deemed representative of the sample from the sub-samples, wherein identity information from a sub-sample about a particular identity is included in the identity information deemed representative of the sample when that particular identity is indicated as present by one or more of the sub-samples analyzed, the amount of that particular identity in the identity information deemed representative of the sample being a weighted combination based on the amount of that particular identity in the sub-samples. In this way useful profiles can be obtained more often than they are at present, with reduced costs and with reduced expertise and time requirements.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: November 15, 2011
    Assignee: Forensic Science Service Ltd.
    Inventors: Martin Bill, Ricky Paul Young
  • Patent number: 8053182
    Abstract: The present invention provides methods and kits for predicting transplant rejection or tolerance. Methods for predicting the probability of cardiac allograft rejection via profiling of peripheral blood gene expression are also provided.
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: November 8, 2011
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Thomas Cappola, Jonathan A. Epstein
  • Patent number: 8043805
    Abstract: Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: October 25, 2011
    Assignee: Vysis, Inc.
    Inventors: Irina A. Sokolova, Steven A. Seelig, Larry E. Morrison, Walter King, Alicia Algeciras-Schimnich
  • Patent number: 8034554
    Abstract: Methods of the invention separate a target nucleic acid from a sample by using at least one capture probe oligonucleotide that contains a target-complementary region and a member of a specific binding pair that attaches the target nucleic acid to an immobilized probe on a capture support, thus forming a capture hybrid that is separated from other sample components before the target nucleic acid is released from the capture support and hybridized to a detection probe to form a detection hybrid that produces a detectable signal that indicates the presence of the target nucleic acid in the sample. Compositions for practicing the methods of the invention include a capture probe oligonucleotide made up a target-complementary region sequence and a covalently linked capture region sequence that includes a member of a specific binding pair.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: October 11, 2011
    Assignee: Gen-Probe Incorporated
    Inventors: Michael M. Becker, Mehrdad R. Majlessi
  • Patent number: 8029984
    Abstract: The invention provides materials and methods for colorectal cancer screening, diagnosis, and therapy.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: October 4, 2011
    Assignee: Licentia, Ltd.
    Inventors: Kari Alitalo, Tatiana Petrova, Antti Nykanen
  • Patent number: 8026352
    Abstract: This invention relates to transgenic winter oilseed rape (WOSR) plants, plant material and seeds, harboring a specific transformation event. It pertains to winter oilseed rape plants, more particularly to a pair of winter oilseed rape plants, which is particularly suited for the production of hybrid seed. More specifically, one plant is characterized by being male-sterile, due to the presence in its genome of a male sterility gene, while the other is characterized by carrying a fertility-restorer gene, capable of preventing the activity of the male-sterility gene. The invention further provides a method for producing hybrid seed, a process for producing a transgenic WOSR plant oil or plant, and a method to identify a transgenic plant, cell or tissue. A kit for identifying the transgenic plants comparing the elite event of the present invention is also described.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: September 27, 2011
    Assignee: Bayer Bioscience, N.V.
    Inventors: Greta De Both, Marc De Beuckeleer
  • Patent number: 8017319
    Abstract: The invention relates to a method and a device for evanescence-based multiplex sequencing of nucleic acid molecules immobilized on a support.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: September 13, 2011
    Inventor: Rudolf Rigler
  • Patent number: 8012686
    Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: September 6, 2011
    Assignee: Academia Sinica
    Inventors: Yuan-Tsong Chen, Shuen-Iu Hung, Wen-Hung Chung, Jer-Yuarn Wu
  • Patent number: 8003319
    Abstract: Techniques for controlling the position of a charged polymer inside a nanopore are provided. For example, one technique includes using electrostatic control to position a linear charged polymer inside a nanopore, and creating an electrostatic potential well inside the nanopore, wherein the electrostatic potential well controls a position of the linear charged polymer inside the nanopore.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: August 23, 2011
    Assignee: International Business Machines Corporation
    Inventors: Stanislav Polonsky, Stephen M. Rossnagel, Gustavo A. Stolovitzky